TACTILE SYSTEMS TECHNOLOGY INC Revenue Disclosure
Note 13. Revenue
We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product:
Year Ended | |||||||||
December 31, | |||||||||
(In thousands) | 2025 | 2024 | 2023 | ||||||
Revenue | |||||||||
Lymphedema products | $ | 278,380 | $ | 259,361 | $ | 241,721 | |||
Airway clearance products | 51,142 | 33,623 | 32,702 | ||||||
Total | $ | 329,522 | $ | 292,984 | $ | 274,423 | |||
Percentage of total revenue | |||||||||
Lymphedema products |
| 84% |
| 89% |
| 88% | |||
Airway clearance products | 16% | 11% | 12% | ||||||
Total |
| 100% |
| 100% |
| 100% | |||
Our revenue by channel, inclusive of sales and rental revenue, for the years ended December 31, 2025, 2024 and 2023, are summarized in the following table:
Year Ended | |||||||||
December 31, | |||||||||
(In thousands) | 2025 | 2024 | 2023 | ||||||
Private insurers and other payers | $ | 168,920 | $ | 175,432 | $ | 148,901 | |||
Veterans Administration | 28,997 | 30,890 | 27,003 | ||||||
Medicare | 80,463 | 53,039 | 65,817 | ||||||
Durable medical equipment distributors | 51,142 | 33,623 | 32,702 | ||||||
Total | $ | 329,522 | $ | 292,984 | $ | 274,423 | |||
Our rental revenue is derived from rent-to-purchase arrangements that typically range from to ten months. As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component.
The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Consolidated Balance Sheet. We bill the patients’ insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by various third party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable.
Rental revenue for the years ended December 31, 2025, 2024 and 2023, was primarily from private insurers. Sales-type lease revenue and the associated cost of revenue for the years ended December 31, 2025, 2024 and 2023, was:
Year Ended | ||||||||||
December 31, | ||||||||||
(In thousands) | 2025 | 2024 | 2023 | |||||||
Sales-type lease revenue | $ | 36,929 | $ | 36,972 | $ | 34,930 | ||||
Cost of sales-type lease revenue |
| 10,690 |
| 11,481 |
| 12,577 | ||||
Gross profit | $ | 26,239 | $ | 25,491 | $ | 22,353 | ||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 17, 2026 | Showing above |
| 2024 | Feb 18, 2025 | |
| 2023 | Feb 20, 2024 | |
| 2022 | Feb 21, 2023 | |
| 2021 | Feb 23, 2022 | |
| 2020 | Feb 23, 2021 | |
| 2019 | Feb 26, 2020 | |
| 2018 | Feb 28, 2019 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.